Phase 0 Clinical Trials: An Answer to Drug Development Stagnation?
Author:
- 1 June 2009
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (16) , 2586-2588
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2009
- Phase 0 clinical trials in oncology: a paradigm shift for early drug development?Cancer Chemotherapy and Pharmacology, 2008
- The Ethics of Phase 0 Oncology TrialsClinical Cancer Research, 2008
- Designing Phase 0 Cancer Clinical TrialsClinical Cancer Research, 2008
- Phase 0 Trials: An Industry PerspectiveClinical Cancer Research, 2008
- Is B-Raf a Good Therapeutic Target for Melanoma and Other Malignancies?Cancer Research, 2008
- Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical PracticeMolecular Interventions, 2007
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- Imaging the pharmacokinetics of [F-18]FAU in patients with tumors: PET studiesCancer Chemotherapy and Pharmacology, 2005
- Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatinCancer Chemotherapy and Pharmacology, 2002